AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
84 hedge funds and large institutions have $171M invested in AVEO Pharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 6 closing their positions.
450% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 6
343% more call options, than puts
Call options by funds: $5.91M | Put options by funds: $1.33M
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
47% more funds holding
Funds holding: 57 → 84 (+27)
21% less capital invested
Capital invested by funds: $218M → $171M (-$46.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$12.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.62M |
| 3 |
EU
Emory University
Atlanta,
Georgia
|
+$1.87M |
| 4 |
AC
Armistice Capital
New York
|
+$1.86M |
| 5 |
Millennium Management
New York
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$19.5M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
-$4.27M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$2.48M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.42M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citigroup
New York
| $7K | +$31 | +1 | +0.4% |
|
77
CIBC Private Wealth Group
Atlanta,
Georgia
| $6K | +$6.21K | +200 | New |
|
|
LTFS
78
Ladenburg Thalmann Financial Services
Miami,
Florida
| $5K | – | – | – |
|
|
CSS
79
Cubist Systematic Strategies
Stamford,
Connecticut
| $2K | -$32.7K | -1,053 | -93% |
|
|
GRP
80
Global Retirement Partners
San Rafael,
California
| $1K | – | – | – |
|
|
II
81
Inspire Investing
Meridian,
Idaho
| $1K | +$1.06K | +34 | New |
|
82
Simplex Trading
Chicago,
Illinois
| $1K | +$2.05K | +66 | New |
|
|
RE
83
RBC Europe
London,
United Kingdom
| $709 | – | – | – |
|
84
Squarepoint
New York
| – | -$388K | -10,636 | Closed |
|
|
OAM
85
Oxford Asset Management
Oxford,
United Kingdom
| – | -$228K | -6,414 | Closed |
|
86
Wolverine Trading
Chicago,
Illinois
| – | -$198K | -5,431 | Closed |
|
|
NC
87
Nexthera Capital
New York
| – | -$190K | -5,200 | Closed |
|
88
UBS Group
Zurich,
Switzerland
| – | -$48.4K | -1,558 | -99% |
|
|
GCP
89
GSA Capital Partners
London,
United Kingdom
| – | -$54K | -1,470 | Closed |
|
|
CCS
90
Crosspoint Capital Strategies
Orinda,
California
| – | -$7K | -204 | Closed |
|
AVEO Hedge Fund Activity: Q4 2017 in Review
84 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2017, worth a combined $171M — down 21% from $218M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new AVEO positions and 6 closed out — a net gain of 27 holders — while 21 added to existing stakes and 13 trimmed.
The largest buyer was Polar Capital, adding an estimated $12.3M. The largest seller was RA Capital Management, cutting an estimated $19.5M.
- 84 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2017, up from 57 in Q3 2017.
- Funds reported $171M of AVEO Pharmaceuticals, Inc. stock for Q4 2017, down 21% quarter-over-quarter.
- 33 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2017 and 6 closed out, a net change of +27 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2017 was Polar Capital, an estimated $12.3M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q4 2017 was RA Capital Management, an estimated $19.5M sold.
Based on aggregated 13F filings for Q4 2017.